Safety first: advancing siRNA therapeutics with AI-driven design and off-target minimization
Year: 2025
Type: article
Abstract: “Being able to bring molecules to patients with diseases that start outside the liver is incredibly inspirational.”Jokūbas Leikauskas, Editor, BioInsights, speaks to Marie Wikström Lindholm, Chief Scientific Officer at Silence Therapeutics, about advances in short-interfering RNA (siRNA) design, the role of artificial intelligence (AI)/machine learning (ML) in oligonucleotide development, strategies for minimizing off-target risks, and future goals for safer, broader therapeutic applications beyond the liver.
Source: Nucleic Acid Insights
Author: Marie Wikström Lindholm
Institution: Silence Therapeutics (Germany)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4417328528
FWCI:
Cites:
Cited by:
Related to: